Medications Development for the Treatment of Cannabis Related Disorders (MTC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01204723
Recruitment Status : Completed
First Posted : September 17, 2010
Last Update Posted : June 1, 2012
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
University of Virginia

September 14, 2010
September 17, 2010
June 1, 2012
August 2009
January 2012   (Final data collection date for primary outcome measure)
  • withdrawal symptom severity, measured on a 0 (not at all) to 3 (severe) scale [ Time Frame: collected on each study day ]
    Subjective experience of withdrawal symptoms for cannabis, tobacco, and both (eg: Irritability, Sleep difficulty, Chills, Nervousness)
  • "craving" measured using the Marijuana craving questionaire and the tobacco craving questionaire [ Time Frame: collected on each study day ]
    Subjective measures of craving for cannabis, tobacco, and both Questionaires are anchored with strongly disagree to strongly agree (1-7)
  • reinforcing effects, as measured using the Multiple Choice Questionaire [ Time Frame: collected each day of study ]
    Reinforcement value of cannabis and tobacco as measured by preference for money over the administration of either drug; questionaire has 70 questions and money value vs. drug ranges from 25 cents to 25 dollars 1-70.
Same as current
Complete list of historical versions of study NCT01204723 on Archive Site
  • sleep quality [ Time Frame: collected on each study day ]
    A VAS sleep questionnaire will be used each morning to assess daily sleep quality.
  • Neurocognitive Function [ Time Frame: collected on days 1-4 of the study ]
    The purpose of examining the neurocognitive function of our participants on days 1-4 is to examine the safety of the co-administration of aprepitant at 160 mg/day with oral THC (dronabinol 10 mg) on brain function. Tasks used are the DSST - The Digit Symbol Substitution Test measures the learning of integrating visual and motor skills, and the SRTT- The Simple reaction Time Task is a well validated computerized test for assessing the effects of psychoactive drugs on performance.
  • Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: each day of study ]
    Blood pressure, pulse, and a Systematic Assessment For Treatment Emergent Events (SAFTEE) are collected daily. Electrocardiograms (EKGs) are collected at baseline and discharge.
Same as current
Not Provided
Not Provided
Medications Development for the Treatment of Cannabis Related Disorders
Medications Development for the Treatment of Cannabis Related Disorders
The primary objective of this application is to test the neurobehavioral mechanisms and effects of aprepitant as a new cessation agent for cannabis, tobacco or both.
Stress (emotional, physical, social) facilitates drug seeking behavior through the activation of the HPA axis, autonomic nervous system, and brain DA systems. Furthermore, alterations within several neuropeptide systems (CRF, Substance P, and others) also contribute to the role of stress in addiction. Central to this project is that anxiety and stress responses are modulated by substance P and its preferred target, the NK1 receptor. Therefore the aim of this pilot clinical trial is to determine the safety and efficacy of aprepitant (a neurokinin 1 (NK1) receptor antagonist). We hypothesize that the NK1 receptor antagonist, aprepitant, will be safe, tolerable and efficacious at reducing the withdrawal symptoms, cue craving, and reinforcement value for both cannabis and tobacco resulting from the cessation of either or both drugs. We will assess this hypothesis in the context of a carefully controlled human laboratory study in which subjects (N=72) will be randomized in a 3 x 2 factorial design to one of 3 behavioral conditions; a) withdrawn from both substances, b) withdrawn from tobacco only, or c) withdrawn from cannabis only, and to receive one of 2 medication dose conditions: placebo or aprepitant (160 mg/day). Medication will be administered for 5 days, followed by a cue challenge, choice procedure, and then a consequence (i.e., oral cannabis or a cigarette or money) also on day 5.
Phase 1
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
  • Nicotine Withdrawal
  • Marijuana Dependence
  • Cannabis Dependence
  • Nicotine Dependence
  • Cannabis Abuse
  • Drug: Placebo Aprepitant
    Placebo Aprepitant 0 mg once daily for 5 days
  • Drug: Active Aprepitant
    Active Aprepitant 160 mg once daily for 5 days
  • Experimental: Behavioral Condition 1
    Nicotine patch (21 mg) plus placebo oral cannabis (0 mg; 3 times a day on days 2-4, given once on day 5)
    • Drug: Placebo Aprepitant
    • Drug: Active Aprepitant
  • Experimental: Behavioral Condition 2
    Placebo nicotine patch (0 mg) plus oral cannabis (10 mg, 3 times each day, days 2-4, day 5 given once)
    • Drug: Placebo Aprepitant
    • Drug: Active Aprepitant
  • Experimental: Behavioral Condition 3
    Placebo nicotine patch (0 mg) plus placebo oral cannabis (0 mg, 3 times each day days 2-4, day 5 given once)
    • Drug: Placebo Aprepitant
    • Drug: Active Aprepitant
Gunderson EW, Haughey HM, Ait-Daoud N, Joshi AS, Hart CL. A survey of synthetic cannabinoid consumption by current cannabis users. Subst Abus. 2014;35(2):184-9. doi: 10.1080/08897077.2013.846288.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
April 2012
January 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Must meet DSM-IV/ICD-10 criteria for cannabis abuse or dependence
  • Must be non-treatment seeking individuals
  • Participant does not meet DSM-IV criteria for any current (i.e., criteria met at any point in the past 30 days) dependence on a substance other than alcohol, nicotine, caffeine, or marijuana or physiological dependence on alcohol requiring medical detoxification.
  • No subjects who have trouble reading the English language or visual or hearing problems that may interfere with the collection of data
  • Not currently taking other medications (with the exception of oral contraceptives) that would preclude safe participation in this study
  • Must test negative for pregnancy prior to inclusion
  • females using birth control pills must agree to use a condom during intercourse for 1 month after participation in study because the study medication will decrease the effectiveness of the birth control pill rendering it ineffective
  • Should be in general good health
  • No evidence of recent use of other illicit drugs on a urine toxicity screen prior to admission

Exclusion Criteria:

  • Major current (within last 90 days) Axis I psychopathology (e.g., major depressive disorder, bipolar disorder, schizophrenia)
  • Presence of significant medical illness (e.g., diabetes, cardiovascular disease, hypertension, cancer, epilepsy, kidney disease)
  • Current, repeated illicit drug use (other than marijuana)
  • Subject is breastfeeding or pregnant
  • Concurrent therapy with drugs known to inhibit CYP3A4 activity
  • Request for drug treatment
  • Current parole or probation
  • Recent history of significant violent or suicide behavior
  • Allergic to sesame oil
Sexes Eligible for Study: All
18 Years to 45 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
R01DA027131 ( U.S. NIH Grant/Contract )
Not Provided
Not Provided
University of Virginia
University of Virginia
National Institute on Drug Abuse (NIDA)
Principal Investigator: Heather M Haughey, Ph.D. University of Virginia School of Medicine, Dept. Psychiatry and Neurobehavioral Sciences
University of Virginia
May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP